Virax Financial Statements From 2010 to 2025

Stocks USA . 
Stock . Virax Biolabs Group
VRAX Stock  USD 2.18  0.04  1.87%   
Virax Biolabs financial statements provide useful quarterly and yearly information to potential Virax Biolabs Group investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Virax Biolabs financial statements helps investors assess Virax Biolabs' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Virax Biolabs' valuation are summarized below:
Gross Profit
50.6 K
Market Capitalization
9.5 M
Enterprise Value Revenue
30.1624
Revenue
156.4 K
Earnings Share
(2.61)
We have found one hundred twenty available fundamental trend indicators for Virax Biolabs Group, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Virax Biolabs Group current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

Virax Biolabs Total Revenue

147,816

Check Virax Biolabs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virax Biolabs' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 88.1 K or Interest Expense of 28.3 K, as well as many indicators such as Price To Sales Ratio of 10.3, Dividend Yield of 0.0 or PTB Ratio of 0.26. Virax financial statements analysis is a perfect complement when working with Virax Biolabs Valuation or Volatility modules.
  
Check out the analysis of Virax Biolabs Correlation against competitors.

Virax Biolabs Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.4 M6.3 M1.6 M
Slightly volatile
Short and Long Term Debt Total210.1 K201.9 K535 K
Slightly volatile
Other Current Liabilities54 K56.8 K751.6 K
Slightly volatile
Total Current Liabilities144.4 K152 K991.7 K
Slightly volatile
Accounts Payable39 K41.1 K217.3 K
Very volatile
Cash2.9 M4.1 M1.3 M
Slightly volatile
Cash And Short Term Investments2.9 M4.1 M1.3 M
Slightly volatile
Common Stock Shares Outstanding1.4 M2.3 M1.3 M
Slightly volatile
Liabilities And Stockholders Equity3.4 M6.3 M1.6 M
Slightly volatile
Total Liabilities295.1 K310.7 K1 M
Slightly volatile
Total Current Assets3.1 M5 M1.4 M
Slightly volatile
Accumulated Other Comprehensive Income28.8 M27.5 M8.7 M
Slightly volatile
Capital Stock3.1 K3 K781
Slightly volatile
Short Term Debt41 K43.2 K503.5 K
Slightly volatile
Common Stock3.1 K3 K781
Slightly volatile
Short Term Investments48.6 K88.9 K21 K
Slightly volatile
Property Plant And Equipment Gross1.5 M1.4 M262.3 K
Slightly volatile
Short and Long Term Debt117 K131.6 K143.5 K
Slightly volatile
Intangible Assets42.6 K44.8 K153.5 K
Slightly volatile

Virax Biolabs Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization88.1 K92.8 K167.9 K
Slightly volatile
Interest Expense28.3 K24.2 K65.4 K
Slightly volatile
Selling General Administrative2.7 M5.3 M1.6 M
Slightly volatile
Selling And Marketing Expenses29 K30.6 K16.3 K
Slightly volatile
Other Operating Expenses8 M7.7 M2.4 M
Slightly volatile
Research Development1.9 M1.8 M441.6 K
Slightly volatile
Total Operating Expenses7.9 M7.5 M2.3 M
Slightly volatile
Minority Interest4.8 K5 K23.1 K
Slightly volatile

Virax Biolabs Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings29.6 K31.1 K472 K
Slightly volatile
Begin Period Cash Flow11.3 M10.8 M2 M
Slightly volatile
Total Cash From Financing Activities1.8 M1.9 M1.7 M
Slightly volatile
End Period Cash Flow2.9 M4.1 M1.3 M
Slightly volatile
Change To Netincome1.8 M1.7 M452.8 K
Slightly volatile
Issuance Of Capital Stock2002111.2 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.310.841.5 K
Slightly volatile
Days Sales Outstanding480458156
Slightly volatile
Average Payables112.3 K118.2 K426.1 K
Slightly volatile
Stock Based Compensation To Revenue7.077.44166
Slightly volatile
Capex To Depreciation9.0310.1711.0827
Slightly volatile
Inventory Turnover3.112.024.8292
Slightly volatile
Days Of Inventory On Hand307187194
Slightly volatile
Payables Turnover2.192.090.6175
Slightly volatile
Sales General And Administrative To Revenue25.1226.4486.5563
Slightly volatile
Average Inventory16.8 K18.9 K20.6 K
Slightly volatile
Research And Ddevelopement To Revenue11.648.998.3168
Slightly volatile
Capex To Revenue15.558.5618.9039
Slightly volatile
Cash Per Share1.721.640.8919
Slightly volatile
Days Payables Outstanding1351421.7 K
Very volatile
Income Quality0.91.070.9445
Slightly volatile
Intangibles To Total Assets0.0150.01040.0169
Slightly volatile
Current Ratio24.5223.355.2928
Slightly volatile
Receivables Turnover0.780.8391.9661
Slightly volatile
Graham Number9.212.797.1272
Slightly volatile
Capex Per Share0.30.520.2239
Slightly volatile
Average Receivables87.1 K98 K106.9 K
Slightly volatile
Revenue Per Share0.07780.08970.078
Slightly volatile
Interest Debt Per Share0.260.140.5219
Slightly volatile
Debt To Assets0.04470.04721.1251
Slightly volatile
Operating Cycle443645265
Slightly volatile
Days Of Payables Outstanding1351421.7 K
Very volatile
Ebt Per Ebit1.141.191.108
Slightly volatile
Quick Ratio24.1823.035.225
Slightly volatile
Net Income Per E B T1.111.151.0648
Pretty Stable
Cash Ratio20.0919.134.4371
Slightly volatile
Days Of Inventory Outstanding307187194
Slightly volatile
Days Of Sales Outstanding480458156
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.891.071.0438
Very volatile
Fixed Asset Turnover0.110.130.139
Slightly volatile
Debt Ratio0.04470.04721.1251
Slightly volatile
Price Sales Ratio10.310.841.5 K
Slightly volatile
Asset Turnover0.03120.03282.8491
Slightly volatile

Virax Biolabs Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.6 M1.7 M6.3 M
Slightly volatile

Virax Fundamental Market Drivers

Cash And Short Term Investments3.6 M

Virax Upcoming Events

27th of September 2023
Upcoming Quarterly Report
View
30th of June 2023
Next Fiscal Quarter End
View
12th of June 2024
Next Fiscal Year End
View
31st of March 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Virax Biolabs Financial Statements

Virax Biolabs investors use historical fundamental indicators, such as Virax Biolabs' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virax Biolabs. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue44 K46.2 K
Total Revenue140.8 K147.8 K
Cost Of Revenue95.2 K48.5 K
Stock Based Compensation To Revenue 7.44  7.07 
Sales General And Administrative To Revenue 26.44  25.12 
Research And Ddevelopement To Revenue 8.99  11.64 
Capex To Revenue 8.56  15.55 
Revenue Per Share 0.09  0.08 
Ebit Per Revenue(47.76)(50.15)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
BTCBitcoin
TRXTRON
BNBBinance Coin

Additional Tools for Virax Stock Analysis

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY